Loading clinical trials...

A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1

A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants

A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SEP-479 in Healthy Adult Participants

NCT07433179•Septerna, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects of oral SEP-479 in healthy adult participants.

Eligibility

Age

21 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Subjects who are able and willing to provide informed consent
•2. Aged 21 to 60 years at the time of consent
•3. Have a BMI within the range 18.0 to 32.0 kg/m2
•4. In general good health

Exclusion Criteria

•1. Any condition, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
•2. Have clinically significant abnormalities on clinical laboratory results.
•3. Participation in other clinical trials recently/currently

Key Dates

Start Date

March 1, 2026

Primary Completion Date

February 1, 2027

Completion Date

February 1, 2027

Last Updated

February 25, 2026

Enrollment

150

ESTIMATED participants

Conditions

Healthy Volunteers

Interventions

SEP-479

DRUG

Placebo

OTHER

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

A Study of ENX-104 in Healthy Participants

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Single-dose,First-in-human of KLA478